Advertisement
Home »

Benefit of Nivolumab/Ipilimumab in MSI-H/dMMR Metastatic Colorectal Cancer Maintenance Beyond First Line

Jun 07, 2024

REFERENCES & ADDITIONAL READING

  1. Andre T, et al. Ann Oncol. 2022;33:1052-1060.
  2. Lens H-J, et al. Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded efficacy analysis from CheckMate 8HW. Abstract 3504, ASCO Annual Meeting 2024, 31 May-4 June, Chicago, IL, USA.

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement